Connect with us

Health

US Tariffs on Pharmaceuticals Could Spark Global Trade Disruptions

Published

on

The pharmaceutical industry is bracing for potential upheaval as the United States considers imposing tariffs on drug imports, a move that could send shockwaves across global markets. President Donald Trump has signaled his intent to impose a 25% tariff on pharmaceuticals as part of a broader strategy to bring drug manufacturing back to the US.

Speaking from the Oval Office on Wednesday night, Trump confirmed his administration’s plans to target the pharmaceutical sector.

“We’re going to be doing tariffs on pharmaceuticals to bring our pharmaceuticals back,” he stated.

While the move aims to bolster domestic production, experts warn that the tariffs could lead to unintended consequences, including higher drug prices and supply chain disruptions that would impact both American and European companies. The US, a major importer of pharmaceuticals, heavily depends on European manufacturers for specialized medications. In 2023 alone, the US imported $170 billion (€157 billion) worth of pharmaceutical products, with $127 billion (€117 billion) coming from the EU.

European Markets at Risk

European pharmaceutical firms are particularly vulnerable to the proposed tariffs. Ireland, a key hub for American pharmaceutical companies, could face severe economic repercussions. In 2023, Ireland exported over €80 billion worth of pharmaceuticals to the US, accounting for more than half of its total exports. Major US firms like Pfizer, Johnson & Johnson, and Eli Lilly have significant operations in Ireland, and potential tariffs could lead to job losses and reduced investment.

Denmark’s pharmaceutical sector, especially Novo Nordisk, is also at risk. The company, a leader in diabetes and obesity treatments, generates over 50% of its revenue from the US market. Increased costs due to tariffs could impact American patients while also denting Denmark’s economic growth. The success of Novo Nordisk’s weight-loss drugs like Ozempic and Wegovy has been a major driver of Denmark’s GDP, contributing nearly half of its economic growth in 2023.

Impact on Other European Nations

Beyond Ireland and Denmark, other European pharmaceutical hubs would also feel the strain. Belgium, home to Pfizer’s major European production facilities, exported over $73 billion in pharmaceuticals in 2024, with a quarter of those exports going to the US. Germany’s pharmaceutical and biotech industries, including major players like Bayer and BioNTech, could also face setbacks. France, Italy, and Switzerland—key exporters of vaccines, generics, and high-value specialty drugs—would experience supply chain disruptions and financial strain.

EU Retaliation on the Horizon?

If the US proceeds with tariffs, the European Union may impose retaliatory measures targeting American pharmaceutical companies. The European Commission is reportedly exploring countermeasures, including higher export costs for US firms such as Pfizer, Merck, and Johnson & Johnson.

Additionally, the EU could prioritize domestic pharmaceutical companies in government contracts and revive stalled regulatory reforms, such as the General Pharmaceutical Legislation (GPL) reform, which aims to strengthen Europe’s pharmaceutical sovereignty. The recently proposed Critical Medicines Act could also serve as a framework to counterbalance US trade policies.

With negotiations ongoing, the global pharmaceutical industry is closely watching developments, as any trade war in this sector would have far-reaching consequences for businesses, patients, and healthcare systems on both sides of the Atlantic.

 

Health

Papua New Guinea Launches Emergency Polio Response After New Cases Detected

Published

on

Health authorities in Papua New Guinea have launched an urgent national vaccination campaign following the detection of two polio cases in children, marking the country’s first confirmed outbreak of the virus since 2018.

The Ministry of Health confirmed this week that poliovirus was found in two otherwise healthy children during routine screenings. Subsequent testing of sewage samples in Lae, the country’s second-largest city, verified that the virus is circulating in the community.

Health Minister Elias Kapavore described the situation as “serious but manageable” and urged swift action. “We’ve dealt with this before and know what works,” he said in a public statement, referring to a previous outbreak in 2018 that resulted in 26 cases of paralysis.

Although Papua New Guinea was declared polio-free in 2000, the recent cases underscore the country’s vulnerability due to persistently low vaccination rates among children. Polio, a highly contagious viral disease, primarily affects children under five and can lead to irreversible paralysis or death in severe cases. The disease has been largely eradicated globally, with only a few endemic regions remaining, such as Afghanistan and Pakistan.

The United Nations Children’s Fund (UNICEF) is working closely with the government to support the emergency vaccination drive. “While the focus right now is on stopping this outbreak, we must take this opportunity to boost routine immunisation to 90 per cent and protect children long-term,” said Dr Veera Mendonca, UNICEF’s representative in Papua New Guinea.

Mendonca emphasised that a long-term strategy to raise routine immunisation coverage is essential to prevent future outbreaks. UNICEF is also assisting in disease surveillance and public education efforts to raise awareness of the risks posed by polio and the importance of vaccination.

The outbreak response will target communities across the country, with particular focus on areas with the lowest immunisation coverage. Health officials are urging parents to ensure their children receive the polio vaccine, which remains the only effective way to prevent infection.

With a population of nearly 12 million and significant logistical challenges in remote areas, ensuring high vaccination coverage will be a complex task. However, authorities remain confident in their ability to contain the outbreak with coordinated action and international support.

Continue Reading

Health

Healthy Diet May Delay Onset of Menstruation, Study Finds

Published

on

A healthy diet may help delay the onset of menstruation in young girls, potentially reducing their risk of several health issues later in life, according to new research published in the journal Human Reproduction.

The study, conducted by researchers at the Fred Hutchinson Cancer Center in the U.S., followed over 7,500 girls between the ages of 9 and 14 to explore the link between dietary habits and the timing of their first menstrual periods. Girls who adhered to the healthiest diets were found to be 16% less likely to experience early menstruation compared to those with the poorest dietary habits.

In contrast, girls who consumed the most inflammatory foods — such as processed meats, sugary drinks, and refined carbohydrates — were 15% more likely to begin menstruating at an earlier age. These results were independent of body size, reinforcing the impact of diet quality regardless of a child’s weight or height.

These findings demonstrate the importance of a healthy diet regardless of body size,” said Dr. Holly Harris, lead author of the study and associate professor at Fred Hutchinson Cancer Center. “This is particularly relevant as early menstruation has been associated with long-term health risks including obesity, type 2 diabetes, cardiovascular disease, and breast cancer.”

Typically, girls begin puberty between the ages of 8 and 13, with menstruation occurring roughly two years after breast development. However, a trend toward earlier onset of puberty has raised concerns among health professionals, especially given its links to chronic illnesses in adulthood.

While the study highlights a possible role for diet in influencing menstrual timing, some experts have cautioned against drawing firm conclusions. Dr. Imogen Roger, a research fellow at Brighton and Sussex Medical School, noted that the data may reflect “reverse causation” — suggesting that the timing of puberty itself might influence dietary choices, rather than the reverse.

Diet was assessed close to the time of menarche for many of the girls,” Roger told Euronews Health. “We know that diet quality can decline during adolescence, so the association may not be entirely one-way.”

Nonetheless, researchers agree that ensuring children have access to nutritious foods — particularly during the crucial developmental window around puberty — is vital. Harris emphasized the importance of school meal programmes grounded in evidence-based nutrition.

This research reinforces the need for equitable access to healthy meals for all children and adolescents, especially through school-based initiatives,” she said.

Continue Reading

Health

Europe Pays Less for Medicines Than the U.S., but Prices Still Vary Widely by Country

Published

on

As former U.S. President Donald Trump reignites debate over America’s high drug prices, attention is once again turning to how Europe manages to pay far less for the same medicines—even if pricing remains inconsistent across the continent.

Trump, speaking to journalists on Monday, criticized the European Union for what he called “brutal” and “nasty” tactics in negotiating with pharmaceutical companies. He announced a proposal to link U.S. drug prices to the lowest rates paid by other wealthy nations, declaring: “We’re going to pay what Europe pays.”

According to a RAND Corporation analysis, the U.S. spent $617.2 billion (€542.7 billion) on pharmaceuticals in 2022—nearly three times the €205.3 billion spent by 24 European countries combined.

While it’s true that Europeans generally pay less, the picture within the region is far from uniform. A report by the World Health Organization (WHO) found that drug prices vary widely across Europe, largely due to confidential negotiations with drugmakers, national budget constraints, and differing approaches to price regulation.

In Switzerland, per capita spending on medicines reached €525, whereas Croatia spent just €262. These discrepancies reflect not only national income levels but also the complex and opaque nature of price-setting in the region. “There’s essentially no transparency,” said Huseyin Naci, an associate professor of health policy at the London School of Economics.

Many European countries base their pricing on what other nations pay and use cost-effectiveness assessments to determine value. England and Sweden emphasize whether a drug justifies its cost, while Germany looks at how much additional benefit it offers over existing treatments.

Still, costs have risen across the continent. In Germany, for instance, hospital drug prices increased 11.5% from 2012 to 2022, while retail pharmacy prices rose 2.6% in the same period. Health insurers have warned that rising prices are putting pressure on public health budgets.

If U.S. policy changes or drug companies push European nations to raise their prices, it would be highly disruptive,” Naci said.

European nations also differ in how drug costs are shared between public systems and individuals. In Cyprus, 90% of medicine expenses were covered by government or mandatory schemes in 2022. In Bulgaria, that figure was only 23%. Meanwhile, patients in some countries still pay out-of-pocket or through co-payments, depending on the condition being treated.

Despite lower overall spending, experts caution that European healthcare systems are already stretched thin. “There’s not much room left to absorb higher pharmaceutical costs,” Naci said.

Continue Reading

Trending